Lalistat as a new antiviral agent
The present new therapeutic lysosomal lipase A antagonist Lalistat is a convenient and reliable pharmaceutical agent to prevent virus infections such as HCV, Influenza Typ A (H5N1) and other virus infections without any risks of reinfections and development of resistance mutations.
Further information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Magnetization by laser pulse
Research team identifies new details of a promising phenomenon. To magnetize an iron nail, one simply has to stroke its surface several times with a bar magnet. Yet, there is…
Turn cells into recording devices to unlock secrets of disease
Seattle Hub for Synthetic Biology launched by Allen Institute, Chan Zuckerberg Initiative, and the University of Washington will turn cells into recording devices to unlock secrets of disease. First-of-its-kind research…
Physicists ‘entangle’ individual molecules for the first time
…hastening possibilities for quantum information processing. In work that could lead to more robust quantum computing, Princeton researchers have succeeded in forcing molecules into quantum entanglement. For the first time,…
